🇺🇸 FDA
Pipeline program

DIAMICRON 60MG, comprimé sécable à libération modifiée, Placebo S05762, METFORMIN, Forxiga 10 mg film-coated tablets

S005201-175

Phase 3 small_molecule active

Quick answer

DIAMICRON 60MG, comprimé sécable à libération modifiée, Placebo S05762, METFORMIN, Forxiga 10 mg film-coated tablets for Type 2 Diabetes inadequately controlled with dapagliflozin with or without metformin is a Phase 3 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Institut für biomedizinische Analytik NMR-Imaging GmbH
Indication
Type 2 Diabetes inadequately controlled with dapagliflozin with or without metformin
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials